No Data
No Data
Shenzhen Chipscreen Biosciences (688321.SH): The current design capacity of the two production lines for SGLT-2 inhibitors is 0.1 billion tablets.
On September 13th, Chipscreen Biosciences (688321.SH) disclosed the record of investor relations activities, which shows that the company's current design capacity for Selpercatinib is 0.1 billion tablets, and there is currently no shortage. At the same time, the company has completed the installation and commissioning of the Phase III expansion of Selpercatinib's production capacity and is currently conducting process validation production.
Shenzhen Chipscreen Biosciences (688321.SH): The sales volume of Xidabenamine in the first half of 2024 increased by 11.74%.
Chipscreen Biosciences (688321.SH) disclosed in the Investor Relations Activity Record that the sales volume of Xidaben in the first half of 2024 increased by 11.74%. The clinical data of DLBCL was released in June, and the new indications have almost no contribution to the revenue in the first half of the year, it is expected to contribute to the incremental revenue in the second half of the year. The new indication of Xidaben for DLBCL will participate in the national medical insurance negotiation this year.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Shenzhen Chipscreen Biosciences (688321.SH): The company was selected as one of the sixth batch of national specialized, special and new "little giant" enterprises.
On September 9, Guolong announced that Shenzhen Chipscreen Biosciences (688321.SH) recently, according to the official announcement of the sixth batch of specialized, special and new 'little giant' enterprises and the third batch of specialized, special and new 'little giant' enterprises in Shenzhen by the Small and Medium Enterprise Service Bureau of Shenzhen, Shenzhen Chipscreen Biosciences Co., Ltd. has been selected for the national 'sixth batch of specialized, special and new 'little giant' enterprise publicity list', and the publicity period for the selected list has ended.
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) P/S Is On The Mark
Shenzhen Chipscreen Biosciences (688321.SH): Has reserves of research and development projects related to monkeypox.
Shenzhen Chipscreen Biosciences, listed on the Shanghai Stock Exchange, stated on the investor interaction platform on August 16th that the company has reserved research and development projects related to monkeypox, and the CDCS23 project has completed some preclinical work and has excellent antiviral activity.
No Data
No Data